NEW YORK and SAN DIEGO, Nov. 11 /PRNewswire/ -- ChemBridge Research Laboratories, LLC (CRL) and the Experimental Therapeutics Center (ETC) at Memorial Sloan-Kettering Cancer Center, announced today a collaborative agreement where CRL will provide ETC with diverse and targeted collections of small molecules including their PHARMACophore, GPCR and Kinase Targeted Libraries to support the discovery of novel therapeutic agents for the treatment of cancer. In turn, Memorial Sloan-Kettering will profile the biological activity of the CRL libraries against multiple existing and novel molecular targets in its newly established High Throughput Screening (HTS) Core Facility which interacts closely with multiple research groups throughout the Center.
In addition to compound libraries, CRL will also provide access to its various chemistry technologies, including its knowledge based platforms PharMind(R) and PharmaBlock(R) synthons, to stimulate and accelerate early discovery efforts. CRL has the licensing incentive to provide medicinal chemistry support directed to the efficient optimization of hits identified from its libraries. The agreement is for a period of five years. Other terms were not disclosed.
David Scheinberg, M.D., Ph.D., Chairman of the Experimental Therapeutics Center at MSKCC, stated, "The collaboration with CRL is part of our expanding initiative in drug discovery and development at Sloan Kettering. Our goal is for the rapid progression of potential anticancer agents into the clinic." He added, "ETC promotes and facilitates the development of new cancer therapies through wide ranging multidisciplinary activities, from basic chemistry and biology to clinical investigations".
Hakim Djaballah, Ph.D., head of the newly established HTS facility at Sloan-Kettering, added, "We are very pleased to be working with CRL, a premier company for discovery chemistry with a validated high throughput medicinal chemistry capability for lead optimization."
Sven H. Wagner, Ph.D., Associate Director of Business Development of CRL, added, "In this unique partnership between academia and industry we have the ability to make a vital impact on a challenging disease such as cancer. At CRL, we have established an innovative chemistry platform with the potential for facilitating the rapid identification and optimization of small molecular drug candidates with activity against the most challenging biological targets. We are excited about working with a premier cancer center such as Memorial Sloan-Kettering, where excellent basic science and clinical oncology research work so closely together toward the goal of producing new medicines for this devastating disease."
Alexander Chucholowski, Ph.D., Executive Director of Chemistry, commented, "We are impressed by the high degree of talent, focus and energy in which Memorial Sloan-Kettering applies its cutting-edge science to understand and treat a comprehensive range of cancers. We are looking forward to supporting Memorial Sloan-Kettering's important ambitions with CRL's hits-to-lead contributions in our new partnership."
Memorial Sloan-Kettering Cancer Center, http://www.mskcc.org/, is the world's oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide.
ChemBridge Research Laboratories, LLC (CRL), http://www.chembridgeresearch.com/, is a discovery chemistry research company based in San Diego. CRL's state-of-the-art custom built laboratories encompass high-throughput, medicinal, large scale, analytical, and computational chemistry as well as complementary bioassay and early ADMET capabilities. CRL can tackle the most challenging discovery chemistry projects by leveraging its access to a portfolio of unique chemistry tools and knowledge database of validated synthetic methodologies applicable to drug discovery. CRL's growth in the near and long-term will be supported by a balanced portfolio of proprietary products, such as advanced combinatorial libraries against GPCR, Kinases and several other important protein super-families, substantial multi-year strategic collaborations and discovery/medicinal chemistry contract research arrangements with major pharmaceutical and leading biotech companies, as well as proprietary lead identification programs.
ChemBridge Research Laboratories, LLC